Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-324 Extension Study in Hereditary Angioedema
NCT07428499Phase 3Recruiting
- Sponsor
- ADARx Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Jun 2030
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 19
01
Overview
A Phase 3 trial of onvuzosiran in hereditary angioedema (HAE), sponsored by ADARx Pharmaceuticals. Started Apr 2026; status: recruiting.
02
Drugs
onvuzosiran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT07428499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428499.